TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03965650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video coaching exercises
Description: Patients will perform physical exercises following a specifical video coaching program during 6 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine exercises
Description: Routine method by advising and encouraging patients to perform exercises according to the WHO recommendations during the first 3 months of the study.~Thereafter, patients will have access to the video coaching program of physical activities during the following 3 months.
Study: NCT05227729

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of blood flow in descending aorta by suprasternal ultrasound Doppler technique
Description: While study subjects are in general anesthesia the investigator will perform repeated measurements every 5 min.
Study: NCT06467175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sampling for high molecular weight DNA extraction
Description: 2 EDTA tubes will be taken for the index case, and the DNA will be extracted for sequencing into long-fragments and short-fragments. 1 EDTA tube will be taken for each relative.
Study: NCT04681430

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: transfusion of convalescent plasma (CP) with neutralizing antibodies against anti-SARS-CoV-2 ((titer of at least 1:160)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat Mesilate
Description: Tablets over 7 days, daily dose of 600 mg split into 3 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Camostat Mesilate
Description: Placebo Tablets over 7 days, split into 3 doses

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SoC)
Description: Control Arm for convalescent plasma (CP)
Study: NCT05546528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: G1 will receive the photobiomodulation application with the Laser Therapy XT device, (DMC, São Paulo, Brazil). The laser will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Photobiomodulation- Sham
Description: G2 will receive the photobiomodulation application with the Laser Therapy XT device off. The laser off will be applied for 60 seconds per point, in 2 extraoral points and 2 intraoral points in the region of the parotid glands bilaterally, as well as 1 extraoral point for the submandibular and sublingual glands (totaling 16 points).
Study: NCT06272019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodine gargle
Description: Iodine gargle 0.2 %

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodine gargle
Description: Iodine gargle 0.2 %
Study: NCT05838989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefabricated Orthoses
Description: Participants in this group will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist. Participants will be instructed to wear the orthoses as directed by their healthcare provider.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefabricated Orthoses
Description: Participants in this group will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist. Participants will be instructed to wear the orthoses as directed by their healthcare provider.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: general and lumbrical muscle stretching
Description: Participants in this group will receive supervised general and lumbrical muscle stretching exercises for 10 minutes, three times per week, for 8 weeks. The stretching exercises will be performed under the supervision of a trained therapist and will include a series of exercises designed to stretch the muscles in the hands, wrists, and forearms. In addition, participants will be provided with prefabricated wrist orthoses to wear during the day and at night to provide support and immobilization to the wrist.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this group will receive placebo treatment consisting of gentle wrist and hand movements. The movements will be performed under the supervision of a trained therapist and will consist of gentle range of motion exercises designed to mobilize the joints in the hands and wrists. Participants will not be provided with any orthoses to wear during the study.
Study: NCT05959642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dentapen
Description: Experimental: Controlled Flow Delivery Dentapen according to the manufacturer instructions, It works with standardised 1.8 mL local anaesthetic carpules. The distalingual and mesiolingual line angles are the most effective for multi-rooted upper D teeth.~Articaine hydrochloride 4% with 1:100,000 epinephrine will be injected for each root as shown on a special indicator.The dentist will wait 5 seconds before needle withdrawal. Same steps will be repeated at the mesiolingual line angle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional metal Syringes
Description: Active Comparator: Conventional Injection of infiltration upper d a standard technique for the Injection of infiltration upper d will be used supplemented with long buccal infiltration for the buccal gingiva.~A 27-gauge disposable dental needle will be used to inject Articaine hydrochloride 4% with 1:100,000 epinephrine. The needle will be directed to primary molars
Study: NCT05772988

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine
Description: Beta-alanine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Maltodextrin
Study: NCT05227729

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of blood flow in descending aorta by transoesophageal ultrasound Doppler technique
Description: While study subjects are in general anesthesia the investigator will perform repeated measurements every 5 min.
Study: NCT05026775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Initial Medication Adherence (IMA)
Description: The IMA intervention is a shared-decision making intervention that promotes health literacy and patient participation in the decision making process during the recommendation and prescription of a new drug for the management of a cardiovascular disease and diabetes.~The IMA intervention has four main components: training for healthcare professionals (general practitioners (GP), nurses and community pharmacists) on non-initiation, shared-decision making, health literacy and use of decision aids; intervention decision aids (leaflets and website); implementation of the IMA intervention during the GP's consultation; and information support provided by the nurses and community pharmacists that will use the intervention decision aids to explore the patients's doubts and harmonise and standardise the discourse between primary healthcare professionals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Health professionals in the usual care group will prescribe medication and provide information as usual.
Study: NCT05038761

Intervention type: DEVICE
Intervention: CGM System
Description: Following the manner of observational study, no intervention will be used for the study.~Participants will wear the CGM on abdomen or lower area for no longer than 14 days.

Intervention type: PROCEDURE
Intervention: Standard Venous Blood Glucose Test
Description: Necessary venous blood glucose testing will be performed during the study as clinically required as comparator.
Study: NCT05925608

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs)
Description: CardiALLO™ Human Allogenic Culture-expanded Bone marrow-derived Mesenchymal Stem Cells (hMSCs) delivered with the Helix transendocardial delivery catheter (treatment)

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Diagnostic Catheterization
Description: Left ventricular catheterization with no active therapy
Study: NCT05169671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATH-1020
Description: ATH-1020 in oral capsule form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in oral capsule form
Study: NCT06143410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% Injectable Solution
Description: administration of a bolus of lidocaine 1.5 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline administration as placebo
Description: administration of a bolus of saline solution as a placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol injection
Description: Sedation by total intravenous administration (TIVA) of propofol using target controlled infusion (TCI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol injection
Description: Sedation by total intravenous administration (TIVA) of propofol using target controlled infusion (TCI)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: gastroscopy
Description: esogastroduodenoscopy
Study: NCT04507841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Neoadjuvant niraparib monotherapy with an individualized starting dose of 200mg/day or 300mg/day based on body weight or platelet count. The 28-day treatment cycle consists of 21 days of medication followed by a 7-day break. Two cycles of neoadjuvant niraparib monotherapy were used, and the investigator may choose to have an additional cycle based on the patient's condition.
Study: NCT05428228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TP1
Description: Participants will be administered TP1 during one of the experimental visits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TP2
Description: Participants will be administered TP2 during one of the experimental visits.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered placebo during one of the experimental visits.
Study: NCT06143410

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastroscopy
Description: esogastroduodenoscopy
Study: NCT05792072

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: High-frequency rTMS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: sham rTMS
Study: NCT04906772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: participants received loading of ketamine 1 mg/kg and dexmedetomidine 1µg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr ketamine and 0.25µg/kg/hr dexmedetomidine throughout the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: participants received loading of ketamine 1 mg/kg and propofol 1mg/kg over 10 minutes then continue by a dose of 0.25 mg/kg/hr propofol and 0.25µg/kg/hr dexmedetomidine throughout the procedure.
Study: NCT04373941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.
Study: NCT06606886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tablet Metformin (Group A)
Description: Tablet Metformin 500 mg/dose orally twice a day with meal for 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tablet Hydroxyurea (Group B)
Description: Tablet Hydroxyurea 10-20mg/kg once daily orally with breakfast for 1 year
Study: NCT06612268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etavopivat
Description: Etavopivat will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching Etavopivat will be administered orally.
Study: NCT04495751

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Muscadine grape extract
Description: Four pills twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four pills twice daily.
Study: NCT04364256

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA)
Description: Active or Sham Neuromuscular electrical stimulation. US Food and Drug Administration-approved 2012
Study: NCT04495751

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality of Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Ancillary studies
Study: NCT04364256

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RS-4i Plus Sequential Stimulator (RS Medical, Vancouver, WA)
Description: Active or Sham Neuromuscular electrical stimulation. US Food and Drug Administration-approved 2012
Study: NCT04495751

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participant Feedback
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Participant Feedback
Description: Ancillary studies
Study: NCT05295433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-3705
Description: A sterile liquid for injection
Study: NCT05966805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training group
Description: 12-Week Exercise intervention on mentaL, metabolic, physicaL, spiritual, social, and occupational well-being among shift-working acute care NURSE

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-List Control Group
Description: Control group
Study: NCT06293911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biorepair Plus Parodontgel Intensive
Description: The Biorepair Plus Parodontgel Intensive gel will be used after home oral hygiene once a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo gel
Description: The placebo gel (without hyaluronic acid, Lactobacillus Ferment, Aloe Barbadensis Leaf Juice Powder and lactoferrin) will be used after home oral hygiene once a day.
Study: NCT06633016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-002
Description: ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator Placebo oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the morning followed by 240 mL (8 oz) of water.
Study: NCT06737315

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Submocosal instrumentation using a ultrasonic device (PEEK). Submucosal cleaning
Description: The treatment under study is professional non-surgical, submucosal debridement with ultrasonic instruments with PolyEther Ether Ketone (PEEK)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submocosal instrumentation using a ultrasonic device (PEEK). Submucosal cleaning
Description: The treatment under study is professional non-surgical, submucosal debridement with ultrasonic instruments with PolyEther Ether Ketone (PEEK)
Study: NCT06738069

Intervention type: OTHER
Intervention: Participants are not assigned an intervention as a part of the study
Description: Participants are not assigned an intervention as a part of the study

Intervention type: OTHER
Intervention: Participants are not assigned an intervention as a part of the study
Description: Participants are not assigned an intervention as a part of the study
Study: NCT06740487

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional ET Treatment
Description: Traditional ET includes the following components: (a) psychological education about trauma (sessions 1 and 2), (b) repeated in vivo exposure to trauma-related stimuli (in vivo exercises are assigned as homework during sessions 3 through 9), (c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 - 9; patients listen to session audiotapes for homework between sessions), and (d) relapse prevention strategies and further treatment planning (session 10).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ARET + Traditional ET Treatment
Description: ARET + Traditional ET includes the following components: (a) psychological education about trauma (sessions 1 and 2), (b) repeated in vivo exposure to trauma-related stimuli (in vivo exercises are assigned as homework during sessions 3 through 9), (c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 - 9; patients listen to session audiotapes for homework between sessions), (d) relapse prevention strategies and further treatment planning (session 10), and (e) 30 minutes of each 90 minute session dedicated to ARET. During ARET, the clinician guides participant, who is wearing AR goggles, through preset scenarios during which characters mingle with each other (e.g., grocery store, social gathering), as well as custom scenarios where participant can interact with the character.
Study: NCT06740045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: 10 patients will receive teszpire
Study: NCT06741098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NCR100
Description: Subjects will receive multiple intra-articular NCR100 injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NCR100
Description: Subjects will receive multiple intra-articular NCR100 injections.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal saline
Description: Subjects will receive multiple intra-articular 0.9% Normal saline injections.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.9% Normal saline
Description: Subjects will receive multiple intra-articular 0.9% Normal saline injections.
Study: NCT06738160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalusobasumab
Description: Patients with advanced bone metastases who have not received any prior systemic therapy for non-small cell lung cancer will receive first-line treatment with nalusolimab and bone target lesion SBRT plus conventional dose immune checkpoint inhibitors and chemotherapy, including nalproxolimab 120 mg/time, subcutaneous injection, administered every 4 weeks. For the treatment of SBRT for bone metastases, the dose of 24 Gy/3 F is used for spinal metastases, and 30 Gy/5 F or 35 Gy/5 F is used for non-spinal lesions. Chemotherapy combined with immune checkpoint inhibitor therapy was used in accordance with the guidelines until progression.
Study: NCT06738173

Intervention type: DIAGNOSTIC_TEST
Intervention: Gut microbiome testing
Description: Gut microbiome testing for the characterization of the patient gut microbiome
Study: NCT06741358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glialia
Description: Participants in the PPPD-Glialia group will receive the Glialia supplement, which contains 700 mg of Palmitoylethanolamide (umPEA) along with 70 mg of additional supportive ingredients. Each participant will be instructed to take two soluble sachets daily for a total duration of 60 days. This group aims to evaluate the effects of Glialia on PPPD, with outcomes assessed for neuroinflammation, mental clarity, quality of life, balance, and gait quality.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants assigned to the PPPD-Placebo group will receive a placebo that is designed to be indistinguishable from the Glialia supplement in terms of appearance and packaging. They will also take two soluble sachets daily for 60 days. The purpose of this group is to serve as a control to evaluate the effects of the Glialia supplement by comparing the outcomes with those of the PPPD-Glialia group. The same assessments for neuroinflammation, mental clarity, quality of life, balance, and gait quality will be performed.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Individuals in the Control Group will receive the same Glialia supplement as the PPPD-Glialia group, containing 700 mg of Palmitoylethanolamide (umPEA) and 70 mg of supportive ingredients. They will also take two soluble sachets daily for 60 days. The primary goal for this group is to assess how the Glialia supplement affects neuroinflammation and related outcomes in individuals who have recovered from COVID-19 but do not have PPPD. This comparison will help clarify the potential effects of Glialia in the context of both PPPD and recovery from COVID-19.
Study: NCT06740136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Muscle induced-damage eccentric exercise
Study: NCT06738992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Antiplatelet therapy was initiated on the second day after surgery with oral administration of Aspirin Enteric-coated Tablets (Bayer Aspirin) at a dose of 100 mg once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Anticoagulation therapy was initiated on the second day after surgery, starting at 4.5 mg once nightly, with adjustments made based on changes in the INR value.